ArticleBMC pediatrics2026
LUMINEX technology detects plasma inflammatory factor expression levels in children with severe and non-severe community acquired pneumonia.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the clinical utility of LUMINEX technology in detecting plasma inflammatory factor expression levels (IL-1β, TNF-α, and IL-10) in children with severe and non-severe community-acquired pneumonia (CAP), comparing its performance with traditional ELISA methods for disease severity assessment and prognosis prediction.
methodsThis study enrolled 72 pediatric patients diagnosed with community-acquired pneumonia at our institution between January 2023 and December 2024, comprising 28 severe cases and 44 non-severe cases, along with 80 age-matched healthy controls. Inflammatory marker concentrations [interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10)] were quantified in plasma and serum samples using LUMINEX multiplex analysis and ELISA techniques. Comparative analyses examined inflammatory mediator expression patterns across disease severity groups and evaluated their diagnostic discrimination capacity, while prognostic assessments investigated the predictive value of plasma inflammatory markers.
resultsComparative analysis revealed significantly elevated concentrations of IL-1β, TNF-α, and IL-10 in both plasma and serum samples from severe cases compared to non-severe patients (P < 0.05), with non-severe patients also showing higher levels than healthy controls (P < 0.05). Both LUMINEX-based plasma analysis and ELISA serum measurements demonstrated comparable diagnostic accuracy for severe pneumonia identification. Prognostic evaluation indicated that patients with unfavorable outcomes exhibited increased plasma inflammatory marker levels relative to those with favorable prognoses (P < 0.05). ROC analysis showed superior predictive performance for TNF-α and IL-10 (higher AUC values) compared to IL-1β in forecasting clinical outcomes.
conclusionThe detection of plasma inflammatory cytokines in children with community-acquired pneumonia by LUMINEX technology is helpful to determine the condition and evaluate the prognosis of children, and it is worth promoting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.